JP5976810B2 - ５−置換テトランドリン誘導体、その調製方法及びその使用 - Google Patents

５−置換テトランドリン誘導体、その調製方法及びその使用 Download PDF

Info

Publication number
JP5976810B2
JP5976810B2 JP2014526373A JP2014526373A JP5976810B2 JP 5976810 B2 JP5976810 B2 JP 5976810B2 JP 2014526373 A JP2014526373 A JP 2014526373A JP 2014526373 A JP2014526373 A JP 2014526373A JP 5976810 B2 JP5976810 B2 JP 5976810B2
Authority
JP
Japan
Prior art keywords
alkyl
substituted
heteroaryl
cancer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014526373A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524449A (ja
JP2014524449A5 (enExample
Inventor
ロンツェン シュー
ロンツェン シュー
フランク ロン
フランク ロン
フーウェン シェ
フーウェン シェ
ホンシ ライ
ホンシ ライ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Bensheng Pharmaceutical Co Ltd
Original Assignee
Hangzhou Bensheng Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Bensheng Pharmaceutical Co Ltd filed Critical Hangzhou Bensheng Pharmaceutical Co Ltd
Publication of JP2014524449A publication Critical patent/JP2014524449A/ja
Publication of JP2014524449A5 publication Critical patent/JP2014524449A5/ja
Application granted granted Critical
Publication of JP5976810B2 publication Critical patent/JP5976810B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2014526373A 2011-08-19 2012-08-20 ５−置換テトランドリン誘導体、その調製方法及びその使用 Expired - Fee Related JP5976810B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2011/078622 2011-08-19
CN2011078622 2011-08-19
PCT/CN2012/080384 WO2013026383A1 (zh) 2011-08-19 2012-08-20 5-位碳取代的汉防己甲素衍生物、及其制备方法和应用

Publications (3)

Publication Number Publication Date
JP2014524449A JP2014524449A (ja) 2014-09-22
JP2014524449A5 JP2014524449A5 (enExample) 2015-09-24
JP5976810B2 true JP5976810B2 (ja) 2016-08-24

Family

ID=47745944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014526373A Expired - Fee Related JP5976810B2 (ja) 2011-08-19 2012-08-20 ５−置換テトランドリン誘導体、その調製方法及びその使用

Country Status (6)

Country Link
US (1) US9133207B2 (enExample)
EP (1) EP2767538B1 (enExample)
JP (1) JP5976810B2 (enExample)
CN (1) CN103635475B (enExample)
DK (1) DK2767538T3 (enExample)
WO (1) WO2013026383A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016023404A1 (zh) * 2014-08-15 2016-02-18 贵州省中国科学院天然产物化学重点实验室 双苄基异喹啉衍生物、其制备方法及其在肝病的治疗与预防中的用途
CN107033157B (zh) * 2016-02-03 2020-05-05 贵州省中国科学院天然产物化学重点实验室 双苄基异喹啉衍生物及其在制备用于治疗或预防肿瘤的药物中的用途
CN108904500A (zh) * 2018-08-13 2018-11-30 河北工业大学 双醚键型BBI在抑制Kv10.1离子通道活性中的应用和药物
WO2020150638A1 (en) * 2019-01-18 2020-07-23 City Of Hope Berbamine derivatives and methods of use thereof
CN112125914B (zh) * 2019-06-25 2024-02-13 杭州卫本药业有限公司 5-取代的小檗胺衍生物，其制备方法和应用
CN112480140B (zh) * 2020-12-28 2022-04-01 杭州医学院 C5-位取代汉防己甲素衍生物及其制备方法和应用
CN114031623B (zh) * 2021-11-12 2023-04-11 山西医科大学 一种c14位氨基取代粉防己碱衍生物及其制备和应用
CN116731031A (zh) * 2023-06-16 2023-09-12 贵州药法自然医药科技有限公司 芬氏唐松草碱衍生物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02134382A (ja) * 1988-11-14 1990-05-23 Kaken Shiyouyaku Kk ビスベンジルイソキノリン誘導体
JP2627666B2 (ja) * 1989-07-13 1997-07-09 花王株式会社 抗アレルギー剤
US5025020A (en) 1989-09-28 1991-06-18 Cancer Biologics Of America, Inc. Use of tetrandrine and its derivatives to treat malaria
CN1111160C (zh) * 2000-09-08 2003-06-11 成都康弘制药有限公司 双苄基异喹啉类生物碱和药物组合物及用途
US6617335B1 (en) * 2002-05-02 2003-09-09 Kanghong Usa, Inc. Preparation and drug composition of bis-benzyl-isoquinoline class alkaloids
CN1810247A (zh) * 2005-01-28 2006-08-02 中国医学科学院血液学研究所 小檗胺衍生物ebb在抑制人体肿瘤细胞侵袭转移的药物应用
CN101273989B (zh) * 2008-04-09 2011-02-09 浙江大学 一类小檗胺衍生物及其盐的应用
CN101423519A (zh) * 2008-11-28 2009-05-06 浙江大学 粉防己碱有机酸盐及制备方法和应用
CN101780082B (zh) * 2009-01-20 2015-11-25 张宏 双苄基异喹啉类生物碱在制备抗感染药物增效剂中的用途及其药物组合物
US8722698B2 (en) * 2009-05-19 2014-05-13 City Of Hope Berbamine derivatives
CN102875560B (zh) * 2011-07-15 2014-12-03 复旦大学 5-取代粉防己碱类化合物及其在制备抗癌药增敏剂中的用途

Also Published As

Publication number Publication date
EP2767538B1 (en) 2016-07-13
WO2013026383A1 (zh) 2013-02-28
US20140343047A1 (en) 2014-11-20
US9133207B2 (en) 2015-09-15
DK2767538T3 (en) 2016-12-12
JP2014524449A (ja) 2014-09-22
CN103635475B (zh) 2016-06-08
EP2767538A1 (en) 2014-08-20
CN103635475A (zh) 2014-03-12
EP2767538A4 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
JP2014524449A (ja) ５−置換テトランドリン誘導体、その調製方法及びその使用
CN102234259B (zh) 含笑内酯衍生物,其药物组合物及其制备方法和用途
JP6043361B2 (ja) オレアノール酸アミド化誘導体、その調製方法及び使用
JP6298768B2 (ja) ７−置換ハンファンギチンｂ誘導体、その調製方法及び使用
DK2615092T3 (en) Heterocyclic AMINOBERBAMIN DERIVATIVES, PREPARATION METHOD AND USE THEREOF
US9353146B2 (en) Acylation derivatives of paridis saponins I, preparation method therefor and application thereof
JP6068472B2 (ja) アミノ化ホモハリントニン誘導体、その調製方法及び使用
JP5701387B2 (ja) ベルバミンのジカルボキシミド誘導体、その調製方法及び使用
JP5993455B2 (ja) ホモハリントニンアシル化誘導体、その調製方法及び使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150805

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160622

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160720

R150 Certificate of patent or registration of utility model

Ref document number: 5976810

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees